Literature DB >> 25261461

Moraxella spp. isolated from field outbreaks of infectious bovine keratoconjunctivitis: a retrospective study of case submissions from 2010 to 2013.

John Dustin Loy1, Bruce W Brodersen2.   

Abstract

Infectious bovine keratoconjunctivitis (IBK), also known as pinkeye, is the most costly eye disease of cattle. The principal etiologic agent of IBK is the Gram-negative bacterium Moraxella bovis. However, there have been reports of IBK outbreaks associated with Moraxella bovoculi. A retrospective study of IBK diagnostic cases submitted from July 1, 2010 through October 31, 2013 was conducted. Included in the study were 1,042 Moraxella isolates from 1,538 swabs of lacrimal secretions collected from 282 herds from 30 U.S. states. Moraxella isolates were identified to the species level and were composed of M. bovoculi (701 isolates), M. bovis (295 isolates), Moraxella ovis (5 isolates), and other Moraxella spp. (41). Minimum inhibitory concentrations required for 90% growth inhibition (MIC90) was calculated for representative isolates. The MIC90 values for both M. bovis and M. bovoculi were as follows: ampicillin and ceftiofur: ≤0.25 µg/ml; clindamycin: 2 µg/ml; danofloxacin and enrofloxacin: ≤0.12 µg/ml; florfenicol: 0.5 µg/ml; gentamicin: 1 µg/ml; neomycin: 4 µg/ml; tulathromycin: 2 µg/ml; and tylosin: 8 µg/ml. The MIC90 values for M. bovoculi included the following: chlortetracycline: ≤0.5 µg/ml; oxytetracycline: 4 µg/ml; penicillin: 0.25 µg/ml; spectinomycin: 32 µg/ml; sulfadimethoxine: >256 µg/ml; tiamulin: 1 µg/ml; and trimethoprim-sulfamethoxazole: 4 µg/ml. For M. bovis, MIC90 values included the following: chlortetracycline and oxytetracycline: 1 µg/ml; penicillin: ≤0.12 µg/ml; spectinomycin: 16 µg/ml; sulfadimethoxine: ≤256 µg/ml; tiamulin: ≤0.5 µg/ml; and trimethoprim-sulfamethoxazole: ≤2 µg/ml. The current work describes the frequency of isolation and differences in antimicrobial sensitivity observed among Moraxella isolates from case submissions.
© 2014 The Author(s).

Entities:  

Keywords:  Infectious bovine keratoconjunctivitis; Moraxella bovis; Moraxella bovoculi

Mesh:

Substances:

Year:  2014        PMID: 25261461     DOI: 10.1177/1040638714551403

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  13 in total

1.  Assessment of animal diseases caused by bacteria resistant to antimicrobials: cattle.

Authors:  Søren Saxmose Nielsen; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; Jose Luis Gonzales Rojas; Christian Gortazar Schmidt; Mette Herskin; Virginie Michel; Miguel Angel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Hans Spoolder; Karl Stahl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Jeroen Dewulf; Luca Guardabassi; Friederike Hilbert; Rodolphe Mader; Francesca Baldinelli; Julio Alvarez
Journal:  EFSA J       Date:  2021-12-10

2.  First report of the whole genome of Moraxella bovoculi genotype 1 from India and comparative genomics of Moraxella bovoculi to identify genotype-specific markers.

Authors:  Kumaragurubaran Karthik; Subbaiyan Anbazhagan; Murugesan Ananda Chitra; Ramaswamy Sridhar
Journal:  Arch Microbiol       Date:  2022-10-06       Impact factor: 2.667

3.  Relatedness of type IV pilin PilA amongst geographically diverse Moraxella bovoculi isolated from cattle with infectious bovine keratoconjunctivitis.

Authors:  John A Angelos; Kristin A Clothier; Regina L Agulto; Boguslav Mandzyuk; Morten Tryland
Journal:  J Med Microbiol       Date:  2021-02       Impact factor: 2.472

4.  Large genomic differences between Moraxella bovoculi isolates acquired from the eyes of cattle with infectious bovine keratoconjunctivitis versus the deep nasopharynx of asymptomatic cattle.

Authors:  Aaron M Dickey; John D Loy; James L Bono; Timothy P L Smith; Mike D Apley; Brian V Lubbers; Keith D DeDonder; Sarah F Capik; Robert L Larson; Brad J White; Jochen Blom; Carol G Chitko-McKown; Michael L Clawson
Journal:  Vet Res       Date:  2016-02-13       Impact factor: 3.683

5.  Antibacterial activity and safety of commercial veterinary cationic steroid antibiotics and neutral superoxidized water.

Authors:  Benjamin E Bergstrom; Ahmed Abdelkhalek; Waleed Younis; G Kenitra Hammac; Wendy M Townsend; Mohamed N Seleem
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

6.  Whole genome sequencing of Moraxella bovoculi reveals high genetic diversity and evidence for interspecies recombination at multiple loci.

Authors:  Aaron M Dickey; Gennie Schuller; J Dustin Loy; Michael L Clawson
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

7.  A multiplex real-time PCR assay for the detection and differentiation of five bovine pinkeye pathogens.

Authors:  Wanglong Zheng; Elizabeth Porter; Lance Noll; Colin Stoy; Nanyan Lu; Yin Wang; Xuming Liu; Tanya Purvis; Lalitha Peddireddi; Brian Lubbers; Gregg Hanzlicek; Jamie Henningson; Zongping Liu; Jianfa Bai
Journal:  J Microbiol Methods       Date:  2019-03-29       Impact factor: 2.363

8.  Longitudinal assessment of the bovine ocular bacterial community dynamics in calves.

Authors:  Alison C Bartenslager; Nirosh D Althuge; John Dustin Loy; Matthew M Hille; Matthew L Spangler; Samodha C Fernando
Journal:  Anim Microbiome       Date:  2021-01-30

9.  MALDI-TOF MS Biomarker Detection Models to Distinguish RTX Toxin Phenotypes of Moraxella bovoculi Strains Are Enhanced Using Calcium Chloride Supplemented Agar.

Authors:  Matthew M Hille; Michael L Clawson; Aaron M Dickey; Justin H Lowery; John Dustin Loy
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

10.  Cervid herpesvirus 2 and not Moraxella bovoculi caused keratoconjunctivitis in experimentally inoculated semi-domesticated Eurasian tundra reindeer.

Authors:  Morten Tryland; Javier Sánchez Romano; Nina Marcin; Ingebjørg Helena Nymo; Terje Domaas Josefsen; Karen Kristine Sørensen; Torill Mørk
Journal:  Acta Vet Scand       Date:  2017-04-24       Impact factor: 1.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.